 Peter Mourani
Concepts (499)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 23 | 2021 | 382 | 4.560 |
Why?
| | Heart Arrest | 22 | 2025 | 336 | 3.380 |
Why?
| | Intensive Care Units, Pediatric | 34 | 2025 | 232 | 3.350 |
Why?
| | Cardiopulmonary Resuscitation | 22 | 2025 | 251 | 3.270 |
Why?
| | Respiration, Artificial | 20 | 2024 | 627 | 2.780 |
Why?
| | Pneumonia, Ventilator-Associated | 4 | 2025 | 53 | 2.000 |
Why?
| | Critical Illness | 25 | 2025 | 789 | 1.880 |
Why?
| | Hypertension, Pulmonary | 13 | 2023 | 1903 | 1.840 |
Why?
| | Infant, Premature | 17 | 2021 | 572 | 1.810 |
Why?
| | Microbiota | 9 | 2024 | 759 | 1.790 |
Why?
| | Shock, Septic | 12 | 2024 | 204 | 1.700 |
Why?
| | Prospective Studies | 54 | 2025 | 7512 | 1.600 |
Why?
| | Respiratory Tract Infections | 7 | 2024 | 384 | 1.500 |
Why?
| | Sepsis | 13 | 2025 | 596 | 1.490 |
Why?
| | Child | 103 | 2025 | 21760 | 1.460 |
Why?
| | Respiratory Insufficiency | 6 | 2024 | 311 | 1.440 |
Why?
| | Infant, Newborn | 46 | 2025 | 6051 | 1.360 |
Why?
| | Trachea | 3 | 2017 | 247 | 1.260 |
Why?
| | Infant | 58 | 2025 | 9392 | 1.170 |
Why?
| | Child, Preschool | 52 | 2025 | 10952 | 1.140 |
Why?
| | Skin Pigmentation | 2 | 2025 | 49 | 1.120 |
Why?
| | Oximetry | 2 | 2025 | 102 | 1.080 |
Why?
| | Vascular Diseases | 5 | 2020 | 242 | 1.060 |
Why?
| | Premature Birth | 4 | 2021 | 334 | 0.940 |
Why?
| | Humans | 147 | 2025 | 136962 | 0.920 |
Why?
| | Lung | 10 | 2024 | 4035 | 0.910 |
Why?
| | Critical Care | 6 | 2021 | 599 | 0.900 |
Why?
| | Intubation, Intratracheal | 4 | 2024 | 256 | 0.890 |
Why?
| | Epinephrine | 5 | 2025 | 140 | 0.850 |
Why?
| | Echocardiography | 7 | 2021 | 639 | 0.850 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2022 | 229 | 0.840 |
Why?
| | Accelerometry | 1 | 2024 | 109 | 0.840 |
Why?
| | Heart Ventricles | 2 | 2021 | 738 | 0.810 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 49 | 0.790 |
Why?
| | Influenza, Human | 9 | 2023 | 611 | 0.790 |
Why?
| | Intensive Care Units | 11 | 2025 | 836 | 0.770 |
Why?
| | Male | 76 | 2025 | 67385 | 0.740 |
Why?
| | RNA, Ribosomal, 16S | 4 | 2021 | 551 | 0.740 |
Why?
| | Quality of Life | 13 | 2024 | 2899 | 0.720 |
Why?
| | Ventricular Function, Right | 2 | 2021 | 273 | 0.710 |
Why?
| | Female | 79 | 2025 | 73001 | 0.710 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2019 | 125 | 0.700 |
Why?
| | Gestational Age | 8 | 2025 | 902 | 0.700 |
Why?
| | Patient Discharge | 13 | 2024 | 901 | 0.670 |
Why?
| | Bacteria | 6 | 2025 | 863 | 0.670 |
Why?
| | Adolescent | 48 | 2025 | 21471 | 0.670 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 258 | 0.650 |
Why?
| | Aftercare | 5 | 2024 | 208 | 0.600 |
Why?
| | Nutritional Support | 1 | 2017 | 34 | 0.550 |
Why?
| | Echocardiography, Doppler | 3 | 2018 | 108 | 0.540 |
Why?
| | Respiratory Tract Diseases | 1 | 2019 | 180 | 0.540 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 106 | 0.530 |
Why?
| | Patient Readmission | 3 | 2024 | 699 | 0.520 |
Why?
| | Respiratory Syncytial Viruses | 2 | 2013 | 54 | 0.500 |
Why?
| | Metagenomics | 6 | 2025 | 178 | 0.490 |
Why?
| | Coinfection | 3 | 2022 | 138 | 0.490 |
Why?
| | Risk Factors | 21 | 2024 | 10363 | 0.480 |
Why?
| | Echocardiography, Doppler, Pulsed | 1 | 2015 | 14 | 0.470 |
Why?
| | Pulmonary Artery | 4 | 2024 | 1103 | 0.470 |
Why?
| | Nitric Oxide | 6 | 2022 | 883 | 0.450 |
Why?
| | Energy Intake | 1 | 2017 | 501 | 0.450 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2014 | 20 | 0.430 |
Why?
| | Chlorides | 3 | 2020 | 135 | 0.420 |
Why?
| | Paramyxoviridae Infections | 1 | 2013 | 13 | 0.420 |
Why?
| | Metapneumovirus | 1 | 2013 | 16 | 0.420 |
Why?
| | Retrospective Studies | 28 | 2025 | 15535 | 0.420 |
Why?
| | Myocardial Contraction | 1 | 2015 | 302 | 0.420 |
Why?
| | Pneumonia, Bacterial | 2 | 2025 | 114 | 0.420 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 97 | 0.410 |
Why?
| | Proteomics | 5 | 2024 | 1106 | 0.410 |
Why?
| | Oxygen | 4 | 2024 | 946 | 0.400 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2015 | 160 | 0.400 |
Why?
| | Exercise | 1 | 2024 | 2064 | 0.400 |
Why?
| | Peripheral Vascular Diseases | 1 | 2013 | 103 | 0.380 |
Why?
| | Lung Diseases | 2 | 2010 | 767 | 0.380 |
Why?
| | Pulmonary Embolism | 2 | 2012 | 230 | 0.380 |
Why?
| | Brain Injuries, Traumatic | 3 | 2023 | 371 | 0.370 |
Why?
| | Bacterial Infections | 3 | 2023 | 243 | 0.370 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 500 | 0.370 |
Why?
| | Biomarkers | 11 | 2025 | 4095 | 0.360 |
Why?
| | Energy Metabolism | 1 | 2017 | 919 | 0.360 |
Why?
| | Denys-Drash Syndrome | 1 | 2011 | 4 | 0.360 |
Why?
| | Embolectomy | 1 | 2011 | 13 | 0.360 |
Why?
| | Drug Resistance, Bacterial | 2 | 2025 | 184 | 0.350 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 362 | 0.350 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 314 | 0.350 |
Why?
| | Bereavement | 2 | 2021 | 54 | 0.340 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 539 | 0.340 |
Why?
| | Influenza A virus | 3 | 2020 | 110 | 0.330 |
Why?
| | Cardiopulmonary Bypass | 2 | 2025 | 207 | 0.330 |
Why?
| | Milrinone | 2 | 2021 | 25 | 0.330 |
Why?
| | Wilms Tumor | 1 | 2011 | 86 | 0.330 |
Why?
| | Vasodilator Agents | 3 | 2021 | 319 | 0.320 |
Why?
| | Health Resources | 5 | 2024 | 118 | 0.320 |
Why?
| | Proteome | 2 | 2024 | 470 | 0.320 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1542 | 0.320 |
Why?
| | Acute Kidney Injury | 4 | 2021 | 802 | 0.320 |
Why?
| | Logistic Models | 7 | 2024 | 2066 | 0.310 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2008 | 75 | 0.290 |
Why?
| | Water-Electrolyte Imbalance | 2 | 2020 | 44 | 0.290 |
Why?
| | Coronary Care Units | 2 | 2018 | 19 | 0.290 |
Why?
| | Hemodynamics | 4 | 2025 | 1062 | 0.290 |
Why?
| | Infant, Extremely Premature | 2 | 2020 | 66 | 0.290 |
Why?
| | Sulfones | 1 | 2008 | 109 | 0.280 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 231 | 0.280 |
Why?
| | Multiple Organ Failure | 3 | 2023 | 123 | 0.280 |
Why?
| | Hernia, Diaphragmatic | 1 | 2008 | 66 | 0.280 |
Why?
| | Heparitin Sulfate | 2 | 2024 | 46 | 0.270 |
Why?
| | Heart Diseases | 2 | 2023 | 325 | 0.270 |
Why?
| | Administration, Inhalation | 5 | 2022 | 582 | 0.270 |
Why?
| | Caregivers | 4 | 2024 | 903 | 0.270 |
Why?
| | Time Factors | 11 | 2025 | 6786 | 0.270 |
Why?
| | Staphylococcus | 2 | 2017 | 75 | 0.260 |
Why?
| | Cohort Studies | 13 | 2022 | 5688 | 0.260 |
Why?
| | Length of Stay | 5 | 2025 | 1192 | 0.260 |
Why?
| | Kidney Neoplasms | 1 | 2011 | 395 | 0.260 |
Why?
| | Quality Improvement | 3 | 2022 | 1178 | 0.260 |
Why?
| | Research Design | 4 | 2022 | 1114 | 0.250 |
Why?
| | Staphylococcal Infections | 2 | 2022 | 383 | 0.250 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2021 | 298 | 0.250 |
Why?
| | Piperazines | 1 | 2008 | 343 | 0.250 |
Why?
| | Anti-Bacterial Agents | 5 | 2025 | 1784 | 0.250 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2008 | 201 | 0.240 |
Why?
| | Follow-Up Studies | 8 | 2021 | 5048 | 0.240 |
Why?
| | Hospital Mortality | 8 | 2023 | 895 | 0.240 |
Why?
| | Cloud Computing | 1 | 2025 | 7 | 0.240 |
Why?
| | Spectrophotometry | 1 | 2025 | 59 | 0.230 |
Why?
| | Pregnancy | 10 | 2024 | 6736 | 0.230 |
Why?
| | Bacteriological Techniques | 1 | 2025 | 69 | 0.220 |
Why?
| | Heart Bypass, Right | 1 | 2024 | 17 | 0.220 |
Why?
| | Diastole | 3 | 2019 | 144 | 0.220 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2025 | 53 | 0.220 |
Why?
| | Arteriovenous Malformations | 1 | 2024 | 27 | 0.220 |
Why?
| | Ribosomal Protein S6 | 1 | 2004 | 14 | 0.220 |
Why?
| | Hypercapnia | 1 | 2024 | 53 | 0.220 |
Why?
| | Arteriovenous Fistula | 1 | 2024 | 36 | 0.220 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 31 | 0.210 |
Why?
| | DEAD Box Protein 58 | 2 | 2022 | 9 | 0.210 |
Why?
| | Bradycardia | 1 | 2024 | 52 | 0.210 |
Why?
| | Pregnancy in Diabetics | 2 | 2024 | 122 | 0.210 |
Why?
| | Tunica Intima | 1 | 2004 | 83 | 0.210 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2004 | 446 | 0.210 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2024 | 132 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 4 | 2025 | 3574 | 0.210 |
Why?
| | Treatment Outcome | 12 | 2025 | 10662 | 0.200 |
Why?
| | Pulmonary Veins | 1 | 2024 | 102 | 0.200 |
Why?
| | Respiration | 1 | 2024 | 203 | 0.200 |
Why?
| | Feasibility Studies | 2 | 2024 | 965 | 0.200 |
Why?
| | Employment | 1 | 2024 | 184 | 0.200 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2851 | 0.200 |
Why?
| | Hypoxia | 3 | 2024 | 1108 | 0.200 |
Why?
| | Wounds and Injuries | 2 | 2021 | 746 | 0.200 |
Why?
| | United States | 13 | 2025 | 14945 | 0.190 |
Why?
| | Neuroimaging | 1 | 2025 | 261 | 0.190 |
Why?
| | Cotinine | 1 | 2023 | 77 | 0.190 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 165 | 0.190 |
Why?
| | Hypotension | 1 | 2023 | 114 | 0.190 |
Why?
| | Blood Proteins | 1 | 2024 | 245 | 0.190 |
Why?
| | Age Factors | 6 | 2021 | 3258 | 0.190 |
Why?
| | Receptors, Immunologic | 2 | 2022 | 215 | 0.190 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2022 | 23 | 0.190 |
Why?
| | Viruses | 1 | 2024 | 161 | 0.190 |
Why?
| | Virus Diseases | 1 | 2024 | 212 | 0.190 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2022 | 10 | 0.190 |
Why?
| | Fontan Procedure | 1 | 2024 | 181 | 0.190 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2004 | 257 | 0.190 |
Why?
| | Protein Kinases | 1 | 2004 | 304 | 0.180 |
Why?
| | Indoles | 1 | 2025 | 406 | 0.180 |
Why?
| | Sodium | 1 | 2022 | 199 | 0.180 |
Why?
| | Smoke | 1 | 2023 | 141 | 0.180 |
Why?
| | Central Venous Catheters | 1 | 2022 | 51 | 0.180 |
Why?
| | Glasgow Coma Scale | 4 | 2023 | 191 | 0.180 |
Why?
| | Prone Position | 1 | 2021 | 26 | 0.180 |
Why?
| | Central Venous Pressure | 1 | 2021 | 14 | 0.180 |
Why?
| | Capnography | 1 | 2021 | 16 | 0.180 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2022 | 73 | 0.180 |
Why?
| | Shock | 1 | 2022 | 96 | 0.170 |
Why?
| | ADAMTS4 Protein | 1 | 2020 | 16 | 0.170 |
Why?
| | Thoracic Injuries | 1 | 2021 | 59 | 0.170 |
Why?
| | Iloprost | 1 | 2021 | 45 | 0.170 |
Why?
| | Spinal Injuries | 1 | 2021 | 53 | 0.170 |
Why?
| | Common Data Elements | 1 | 2020 | 14 | 0.170 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2022 | 139 | 0.170 |
Why?
| | Young Adult | 10 | 2024 | 13218 | 0.170 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2021 | 59 | 0.170 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2021 | 347 | 0.170 |
Why?
| | Vasopressins | 1 | 2021 | 59 | 0.170 |
Why?
| | Patient Positioning | 1 | 2021 | 65 | 0.170 |
Why?
| | Multiple Trauma | 1 | 2021 | 100 | 0.170 |
Why?
| | Extremities | 1 | 2021 | 130 | 0.170 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 622 | 0.170 |
Why?
| | Catheterization, Central Venous | 1 | 2022 | 113 | 0.170 |
Why?
| | Parents | 4 | 2021 | 1412 | 0.170 |
Why?
| | Communicable Diseases | 1 | 2022 | 161 | 0.170 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1310 | 0.170 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 93 | 0.160 |
Why?
| | Adult | 13 | 2024 | 37713 | 0.160 |
Why?
| | Epoprostenol | 1 | 2021 | 136 | 0.160 |
Why?
| | Angiogenic Proteins | 1 | 2020 | 15 | 0.160 |
Why?
| | Abdominal Injuries | 1 | 2021 | 119 | 0.160 |
Why?
| | Radiography, Thoracic | 1 | 2021 | 165 | 0.160 |
Why?
| | Brain Injuries | 1 | 2025 | 493 | 0.160 |
Why?
| | Multivariate Analysis | 4 | 2018 | 1484 | 0.160 |
Why?
| | Morbidity | 4 | 2022 | 319 | 0.160 |
Why?
| | Medical Audit | 1 | 2020 | 76 | 0.160 |
Why?
| | Sensitivity and Specificity | 4 | 2025 | 1923 | 0.160 |
Why?
| | Mannose-Binding Lectin | 1 | 2019 | 22 | 0.150 |
Why?
| | Computational Biology | 2 | 2025 | 647 | 0.150 |
Why?
| | Medical Records | 1 | 2020 | 180 | 0.150 |
Why?
| | Nervous System Diseases | 1 | 2022 | 270 | 0.150 |
Why?
| | Cardiotonic Agents | 1 | 2019 | 91 | 0.150 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2020 | 89 | 0.150 |
Why?
| | Pulmonary Circulation | 2 | 2015 | 428 | 0.150 |
Why?
| | Medicine | 1 | 2020 | 124 | 0.150 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 162 | 0.140 |
Why?
| | Reproducibility of Results | 4 | 2020 | 3266 | 0.140 |
Why?
| | CRISPR-Cas Systems | 1 | 2019 | 127 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2371 | 0.140 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 28 | 0.140 |
Why?
| | Calorimetry, Indirect | 1 | 2017 | 84 | 0.140 |
Why?
| | Cardiac Surgical Procedures | 1 | 2023 | 526 | 0.140 |
Why?
| | Toll-Like Receptor 4 | 1 | 2020 | 272 | 0.140 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 37 | 0.140 |
Why?
| | Diabetes, Gestational | 1 | 2022 | 320 | 0.140 |
Why?
| | Academic Medical Centers | 2 | 2017 | 504 | 0.140 |
Why?
| | RNA, Bacterial | 2 | 2024 | 188 | 0.140 |
Why?
| | Medical Staff, Hospital | 1 | 2018 | 81 | 0.140 |
Why?
| | Renal Replacement Therapy | 1 | 2018 | 89 | 0.130 |
Why?
| | Chorioamnionitis | 1 | 2017 | 42 | 0.130 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 68 | 0.130 |
Why?
| | Respiratory System | 1 | 2018 | 155 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 698 | 0.130 |
Why?
| | Blood Pressure | 4 | 2023 | 1786 | 0.130 |
Why?
| | Inservice Training | 1 | 2018 | 119 | 0.130 |
Why?
| | Mutation, Missense | 1 | 2019 | 338 | 0.130 |
Why?
| | Heart Failure | 2 | 2021 | 2046 | 0.130 |
Why?
| | Dysbiosis | 1 | 2018 | 181 | 0.130 |
Why?
| | Hospitalization | 4 | 2023 | 2181 | 0.130 |
Why?
| | Motivation | 1 | 2021 | 583 | 0.130 |
Why?
| | Chronic Disease | 3 | 2022 | 1774 | 0.130 |
Why?
| | Delirium | 1 | 2018 | 89 | 0.130 |
Why?
| | Ultrasonography | 2 | 2025 | 761 | 0.130 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 577 | 0.130 |
Why?
| | Incidence | 3 | 2024 | 2793 | 0.130 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 102 | 0.130 |
Why?
| | Drug Administration Schedule | 2 | 2024 | 749 | 0.130 |
Why?
| | Pneumonia | 1 | 2022 | 633 | 0.120 |
Why?
| | Observer Variation | 1 | 2017 | 347 | 0.120 |
Why?
| | Infant, Low Birth Weight | 2 | 2015 | 141 | 0.120 |
Why?
| | Prognosis | 5 | 2025 | 3931 | 0.120 |
Why?
| | MicroRNAs | 1 | 2022 | 677 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1295 | 0.120 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 16 | 0.120 |
Why?
| | Survival Rate | 4 | 2024 | 1882 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 538 | 0.120 |
Why?
| | Heart Defects, Congenital | 2 | 2024 | 828 | 0.120 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 258 | 0.120 |
Why?
| | Organ Dysfunction Scores | 3 | 2020 | 48 | 0.120 |
Why?
| | Fibroblasts | 1 | 2020 | 997 | 0.120 |
Why?
| | Hyperglycemia | 1 | 2019 | 348 | 0.120 |
Why?
| | Pre-Eclampsia | 1 | 2017 | 189 | 0.120 |
Why?
| | Severity of Illness Index | 5 | 2020 | 2807 | 0.120 |
Why?
| | Needs Assessment | 1 | 2017 | 380 | 0.120 |
Why?
| | Mothers | 2 | 2022 | 758 | 0.120 |
Why?
| | Indiana | 1 | 2015 | 34 | 0.110 |
Why?
| | Medical Informatics | 1 | 2016 | 100 | 0.110 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.110 |
Why?
| | Delphi Technique | 3 | 2020 | 277 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2019 | 367 | 0.110 |
Why?
| | Trauma Centers | 3 | 2022 | 411 | 0.110 |
Why?
| | Vasoconstrictor Agents | 2 | 2025 | 128 | 0.110 |
Why?
| | Bronchiolitis, Viral | 1 | 2013 | 11 | 0.110 |
Why?
| | Hospitals, Pediatric | 3 | 2023 | 506 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2654 | 0.100 |
Why?
| | Aged | 5 | 2024 | 23803 | 0.100 |
Why?
| | Schools, Medical | 1 | 2015 | 149 | 0.100 |
Why?
| | Birth Weight | 1 | 2017 | 508 | 0.100 |
Why?
| | Hyperoxia | 2 | 2024 | 88 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 424 | 0.100 |
Why?
| | Metabolomics | 1 | 2018 | 681 | 0.100 |
Why?
| | Transcriptome | 3 | 2024 | 966 | 0.100 |
Why?
| | Smoking | 2 | 2018 | 1609 | 0.100 |
Why?
| | Signal Transduction | 2 | 2020 | 5047 | 0.100 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 848 | 0.100 |
Why?
| | Hypertension | 2 | 2019 | 1299 | 0.100 |
Why?
| | Patient Care Team | 1 | 2018 | 630 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 49 | 0.100 |
Why?
| | Risk Assessment | 5 | 2018 | 3446 | 0.100 |
Why?
| | Nasopharynx | 2 | 2023 | 73 | 0.100 |
Why?
| | Viral Load | 2 | 2024 | 489 | 0.100 |
Why?
| | Colorado | 4 | 2017 | 4542 | 0.100 |
Why?
| | Adaptive Immunity | 2 | 2024 | 165 | 0.090 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2012 | 89 | 0.090 |
Why?
| | Physicians | 1 | 2021 | 921 | 0.090 |
Why?
| | Risk | 2 | 2012 | 901 | 0.090 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 200 | 0.090 |
Why?
| | Antiphospholipid Syndrome | 1 | 2012 | 33 | 0.090 |
Why?
| | Abbreviated Injury Scale | 2 | 2021 | 20 | 0.090 |
Why?
| | Polysaccharides | 1 | 2012 | 86 | 0.090 |
Why?
| | Precision Medicine | 1 | 2016 | 415 | 0.090 |
Why?
| | Suction | 1 | 2011 | 33 | 0.090 |
Why?
| | Enoxaparin | 1 | 2012 | 63 | 0.090 |
Why?
| | Carbon Dioxide | 2 | 2023 | 266 | 0.090 |
Why?
| | Bacterial Load | 1 | 2011 | 68 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2012 | 302 | 0.090 |
Why?
| | Immunomodulation | 1 | 2012 | 98 | 0.090 |
Why?
| | Grief | 2 | 2021 | 40 | 0.090 |
Why?
| | Pressure | 2 | 2023 | 222 | 0.090 |
Why?
| | RNA, Ribosomal | 1 | 2011 | 167 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 173 | 0.090 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 604 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2017 | 1151 | 0.090 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 235 | 0.080 |
Why?
| | Metagenome | 1 | 2011 | 149 | 0.080 |
Why?
| | Anticoagulants | 2 | 2012 | 652 | 0.080 |
Why?
| | Interferons | 2 | 2022 | 202 | 0.080 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 268 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 2 | 2024 | 488 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1298 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 396 | 0.080 |
Why?
| | Intensive Care, Neonatal | 1 | 2010 | 40 | 0.080 |
Why?
| | Fetal Blood | 1 | 2012 | 333 | 0.080 |
Why?
| | Stakeholder Participation | 2 | 2020 | 79 | 0.080 |
Why?
| | Antihypertensive Agents | 1 | 2013 | 495 | 0.080 |
Why?
| | Influenza Vaccines | 1 | 2014 | 531 | 0.070 |
Why?
| | Blood Glucose | 2 | 2019 | 2184 | 0.070 |
Why?
| | Potassium | 2 | 2022 | 142 | 0.070 |
Why?
| | Sildenafil Citrate | 1 | 2008 | 57 | 0.070 |
Why?
| | Survivors | 2 | 2022 | 500 | 0.070 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2008 | 65 | 0.070 |
Why?
| | Pediatrics | 1 | 2016 | 1061 | 0.070 |
Why?
| | Stem Cells | 1 | 2012 | 595 | 0.070 |
Why?
| | Pulmonary Edema | 1 | 2008 | 112 | 0.070 |
Why?
| | Purines | 1 | 2008 | 176 | 0.070 |
Why?
| | Stroke Volume | 2 | 2021 | 571 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 971 | 0.070 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 5812 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2024 | 1229 | 0.070 |
Why?
| | Diseases in Twins | 1 | 2008 | 159 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2018 | 2622 | 0.060 |
Why?
| | Survival Analysis | 2 | 2022 | 1278 | 0.060 |
Why?
| | Gene Expression | 2 | 2022 | 1480 | 0.060 |
Why?
| | Neovascularization, Physiologic | 2 | 2012 | 179 | 0.060 |
Why?
| | Indoleacetic Acids | 1 | 2025 | 10 | 0.060 |
Why?
| | Phenotype | 2 | 2023 | 3148 | 0.060 |
Why?
| | Clinical Competence | 2 | 2023 | 1114 | 0.060 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 48 | 0.060 |
Why?
| | Neurofilament Proteins | 1 | 2025 | 50 | 0.060 |
Why?
| | Angiopoietin-2 | 1 | 2024 | 15 | 0.060 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 99 | 0.060 |
Why?
| | Cell Division | 2 | 2004 | 789 | 0.060 |
Why?
| | Hypocapnia | 1 | 2024 | 8 | 0.060 |
Why?
| | Cardiac Catheterization | 1 | 2008 | 512 | 0.050 |
Why?
| | Culture Media, Serum-Free | 1 | 2004 | 46 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 165 | 0.050 |
Why?
| | Chromones | 1 | 2004 | 43 | 0.050 |
Why?
| | Diffuse Axonal Injury | 1 | 2023 | 8 | 0.050 |
Why?
| | Cytokines | 1 | 2012 | 2070 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1124 | 0.050 |
Why?
| | Carotid Artery Injuries | 1 | 2004 | 39 | 0.050 |
Why?
| | Androstadienes | 1 | 2004 | 77 | 0.050 |
Why?
| | Aorta | 2 | 2004 | 415 | 0.050 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 64 | 0.050 |
Why?
| | Disaccharides | 1 | 2023 | 19 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2023 | 19 | 0.050 |
Why?
| | Syndecan-1 | 1 | 2023 | 36 | 0.050 |
Why?
| | Oligonucleotides, Antisense | 1 | 2004 | 109 | 0.050 |
Why?
| | Corpus Callosum | 1 | 2023 | 70 | 0.050 |
Why?
| | Glycocalyx | 1 | 2023 | 25 | 0.050 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 31 | 0.050 |
Why?
| | Probability | 1 | 2004 | 306 | 0.050 |
Why?
| | Water-Electrolyte Balance | 1 | 2023 | 32 | 0.050 |
Why?
| | Morpholines | 1 | 2004 | 121 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 174 | 0.050 |
Why?
| | Proteoglycans | 1 | 2023 | 107 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 10 | 0.050 |
Why?
| | Vascular Resistance | 1 | 2004 | 368 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 150 | 0.050 |
Why?
| | Chemotactic Factors | 1 | 2022 | 56 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2004 | 162 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2022 | 2142 | 0.050 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 251 | 0.050 |
Why?
| | Sirolimus | 1 | 2004 | 268 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 559 | 0.050 |
Why?
| | Sodium Bicarbonate | 1 | 2022 | 46 | 0.050 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2024 | 639 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 366 | 0.050 |
Why?
| | White Matter | 1 | 2023 | 143 | 0.050 |
Why?
| | RNA, Viral | 2 | 2017 | 682 | 0.050 |
Why?
| | Cost of Illness | 1 | 2024 | 303 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 62 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 436 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 190 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 462 | 0.040 |
Why?
| | Neonatologists | 1 | 2021 | 7 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 2 | 2004 | 2463 | 0.040 |
Why?
| | Influenza in Birds | 1 | 2020 | 5 | 0.040 |
Why?
| | Patient Acuity | 1 | 2021 | 47 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 451 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 406 | 0.040 |
Why?
| | Leukocyte Common Antigens | 1 | 2020 | 89 | 0.040 |
Why?
| | Blood Gas Analysis | 1 | 2020 | 74 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 839 | 0.040 |
Why?
| | Stromal Cells | 1 | 2020 | 110 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 2115 | 0.040 |
Why?
| | Bicarbonates | 1 | 2020 | 45 | 0.040 |
Why?
| | Birds | 1 | 2020 | 96 | 0.040 |
Why?
| | Software | 1 | 2025 | 662 | 0.040 |
Why?
| | Hematoma, Subdural | 1 | 2019 | 18 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2020 | 75 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2021 | 336 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2021 | 509 | 0.040 |
Why?
| | Skull Fractures | 1 | 2019 | 36 | 0.040 |
Why?
| | Phosphorylation | 1 | 2004 | 1746 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 1059 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 305 | 0.040 |
Why?
| | Intracranial Hemorrhages | 1 | 2019 | 85 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 782 | 0.040 |
Why?
| | Radiation Exposure | 1 | 2019 | 54 | 0.040 |
Why?
| | Child Health | 1 | 2020 | 155 | 0.040 |
Why?
| | Cardiac Output | 1 | 2019 | 167 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 107 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2024 | 819 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2020 | 199 | 0.040 |
Why?
| | Maternal Exposure | 2 | 2012 | 190 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 431 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 689 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 1007 | 0.040 |
Why?
| | American Heart Association | 1 | 2020 | 301 | 0.040 |
Why?
| | Complement Activation | 1 | 2021 | 407 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2021 | 266 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2019 | 304 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3556 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 268 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2020 | 410 | 0.030 |
Why?
| | Seasons | 1 | 2020 | 541 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2004 | 901 | 0.030 |
Why?
| | Rats | 2 | 2004 | 5544 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 171 | 0.030 |
Why?
| | Data Collection | 1 | 2020 | 666 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 323 | 0.030 |
Why?
| | Middle Aged | 3 | 2024 | 33225 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 674 | 0.030 |
Why?
| | Creatinine | 1 | 2019 | 486 | 0.030 |
Why?
| | Animals | 5 | 2020 | 36882 | 0.030 |
Why?
| | Mortality | 1 | 2020 | 356 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2017 | 74 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 842 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2024 | 661 | 0.030 |
Why?
| | Causality | 1 | 2017 | 127 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1730 | 0.030 |
Why?
| | Homozygote | 1 | 2017 | 203 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2018 | 305 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1470 | 0.030 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1747 | 0.030 |
Why?
| | Calcium | 1 | 2022 | 1180 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2020 | 532 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2004 | 4136 | 0.030 |
Why?
| | Point-of-Care Systems | 1 | 2018 | 178 | 0.030 |
Why?
| | Family | 1 | 2020 | 670 | 0.030 |
Why?
| | Social Class | 1 | 2018 | 282 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 392 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 519 | 0.030 |
Why?
| | Registries | 1 | 2023 | 2048 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 857 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 129 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 669 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1626 | 0.030 |
Why?
| | Communication | 1 | 2021 | 911 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2788 | 0.030 |
Why?
| | Proteins | 1 | 2000 | 1003 | 0.030 |
Why?
| | Body Weight | 1 | 2019 | 985 | 0.030 |
Why?
| | Orthomyxoviridae | 1 | 2014 | 40 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 757 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1630 | 0.030 |
Why?
| | Child Health Services | 1 | 2016 | 188 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1999 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 2223 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2080 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2831 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1367 | 0.020 |
Why?
| | Immune System | 1 | 2013 | 178 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1459 | 0.020 |
Why?
| | Depression | 1 | 2021 | 1454 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1699 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1780 | 0.020 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 185 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 329 | 0.020 |
Why?
| | Electrocardiography | 1 | 2012 | 607 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 561 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2013 | 559 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1189 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2708 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2012 | 784 | 0.020 |
Why?
| | Global Health | 1 | 2008 | 383 | 0.010 |
Why?
| | Mice | 1 | 2020 | 17705 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2000 | 234 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2000 | 534 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3661 | 0.010 |
Why?
|
|
Mourani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|